Products for Research Use Only
RegisterLogin

DDO3602

CAT: 0804-HY-178496Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178496Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DDO3602 is a PARP1 HEMTAC degradation agent mediated by HSP90. DDO3602 has good anti-tumor activity and tumor selectivity. DDO3602 induces G2/M phase arrest, DNA damage, and inhibits cell migration by degrading PARP1 in MCF-7 cells (IC50 = 187 nM). DDO3602 can be used for research on cancer such as breast cancer. (Pink: PARP1 Ligand ; Blue: HSP90 Ligand (HY-179203) ; Black: Linker (HY-W015300) )
UNSPSC
12352005
Target
HSP; PARP; PROTACs
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; PROTAC
Field of Research
Cancer
Smiles
CC(C1=C(C=C(C(C(N2CC3=C(C2)C=CC(CN4CCN(CC4)C(CCCCCCC(N5CCN(C(C6=CC(CC7=NNC(C8=CC=CC=C87)=O)=CC=C6F)=O)CC5)=O)=O)=C3)=O)=C1)O)O)C
Molecular Formula
C51H58FN7O7
Molecular Weight
900.05
References & Citations
[1]Liu W, et al. HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment. J Med Chem. 2025 Oct 9;68 (19) :19933-19954.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GTR19275180-01DDO3602

Popular Products